Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target

Bowen Hou,Min Shu,Chenghao Liu,Yunfeng Du,Cuicui Xu,Huijiao Jiang,Jun Hou,Xueling Chen,Lianghai Wang,Xiangwei Wu
DOI: https://doi.org/10.1111/cas.16240
IF: 5.7
2024-06-20
Cancer Science
Abstract:UPF3B is upregulated in hepatocellular carcinoma (HCC) samples and associated with adverse prognosis. UPF3B binds to PPP2R2C, boosting its mRNA degradation and activating the PI3K/AKT/mTOR pathway. E2F6 binds to the UPF3B promoter to facilitate its transcription. The E2F6/UPF3B/PPP2R2C axis could be a promising therapeutic target for treating HCC. RNA‐binding proteins can regulate nucleotide metabolism and gene expression. UPF3B regulator of nonsense mediated mRNA decay (UPF3B) exhibits dysfunction in cancers. However, its role in the progression of hepatocellular carcinoma (HCC) is still insufficiently understood. Here, we found that UPF3B was markedly upregulated in HCC samples and associated with adverse prognosis in patients. UPF3B dramatically promoted HCC growth both in vivo and in vitro. Mechanistically, UPF3B was found to bind to PPP2R2C, a regulatory subunit of PP2A, boosting its mRNA degradation and activating the PI3K/AKT/mTOR pathway. E2F transcription factor 6 (E2F6) directly binds to the UPF3B promoter to facilitate its transcription. Together, the E2F6/UPF3B/PPP2R2C axis promotes HCC growth through the PI3K/AKT/mTOR pathway. Hence, it could be a promising therapeutic target for treating HCC.
oncology
What problem does this paper attempt to address?